EXCLUSIVE: Telo Genomics' Smoldering Multiple Myeloma Prognostic Test Predicts Risk Of Disease Progression, Study Shows
Portfolio Pulse from Vandana Singh
Telo Genomics Corp (OTC:TDSGF) announced that its prognostic test for smoldering multiple myeloma, TeloViewSMM, has been accepted for publication in the American Journal of Hematology. The test demonstrated superior performance in predicting disease progression and stability compared to other oncology tests. The company recently announced a private placement to raise $2 million.
May 30, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Telo Genomics' TeloViewSMM test for smoldering multiple myeloma has been published in the American Journal of Hematology, demonstrating superior performance in predicting disease progression. This could enhance the company's market position and drive revenue growth. The company also announced a $2 million private placement.
The publication of the TeloViewSMM test in a reputable journal validates its effectiveness, potentially increasing demand and market adoption. The recent private placement indicates financial stability and potential for further development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100